



## **Living Cell Technologies Limited**

### **Company Announcement**

## **Strong interim results in Argentinian DIABECCELL<sup>®</sup> trial**

**Date: 22 November 2012 Sydney, Australia and Auckland, New Zealand** – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the results of an interim analysis of its Argentinian Phase I/IIa clinical trial for DIABECCELL, a breakthrough treatment for people with unstable type 1 diabetes.

The results clearly demonstrated a clinically significant reduction in HbA1c, insulin dose and unaware hypoglycaemia, with greater benefit being seen in the patient group receiving the higher dose of DIABECCELL.

The trial, which is ongoing, involves eight patients split into two groups of four. Group one received two 5,000 IEQ/kg doses of DIABECCELL (islet equivalents per kilogram of body weight). Group two received two 10,000 IEQ/kg doses of DIABECCELL. In both groups, the second dose was implanted 12 weeks after the first. At the time of this interim analysis, group one patients were at 24 weeks follow-up after the second transplant, and group two patients were at 12 weeks follow-up after the second transplant.

In the second group of patients (those receiving the higher dose of two implants of 10,000 IEQ/kg) the most significant clinical benefits were:

- average insulin dose reduced by 20%
- a reduction of HbA1c from a pre-transplant average of 8.6% to an average of 6.7% at 12 weeks following the second implant
- up to 70% reduction in unaware hypoglycaemic events.

“Most type 1 diabetic patients who cannot attain reasonable control of their disease by conventional intensive insulin treatment would welcome the degree of control achieved with two doses of DIABECCELL,” said Professor Bob Elliott, Chief Scientific and Medical Officer, LCT. “The reduction in both average daily insulin dose and HbA1c is clear demonstration of the positive effect of the DIABECCELL transplant.”

DIABECCELL is the first islet transplant treatment that does not require ongoing administration of debilitating immunosuppression drugs. DIABECCELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50% interest.

“This interim analysis has been used to inform our 20 patient Phase IIb study, the start of which has also been announced today,” said Dr Andrea Grant, Chief Executive, LCT. “With each trial analysis we grow increasingly confident that DIABECCELL will bring many benefits to patients with unstable type 1 diabetes, and we remain intently focussed on reaching the market by 2016.”

**– Ends –**

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

<b>At the company:</b> Dr Andrea Grant, Chief Executive Officer Tel: +64 9 270 7941 Mobile: +64 21 078 5421 agrant@lctglobal.com	<b>Media enquiries:</b> Sally Raudon Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 402 502 sallyr@botica.co.nz
--	--

### **About DIABECCELL**

Diabetes is usually treated with insulin replacement. A serious and potentially fatal complication associated with intensive insulin replacement therapy is unaware hypoglycaemia. Episodes of unaware hypoglycaemia occur when, without associated symptoms or warning, blood glucose levels drop suddenly. Some patients require significant time and resources from specialist healthcare professionals and have a poor prognosis: lower quality of life, more micro vascular and pregnancy complications and shortened life expectancy.

Treatment with DIABECCELL™ involves transplanting pig pancreatic islet cells into a patient's abdomen to boost insulin production and help regulate blood glucose levels. The cells are encapsulated with IMMUEPEL™ to prevent the immune system rejecting them as foreign. This proprietary technology ensures the cells can deliver their beneficial effects without the patient requiring immunosuppressant drugs.

DIABECCELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50% interest.

For a summary of DIABECCELL's clinical trial programme please see the DIABECCELL clinical trial update on LCT's website ([www.lctglobal.com](http://www.lctglobal.com)) or direct link <http://tinyurl.com/b3lgucw>

### **About Living Cell Technologies**

Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUEPEL™ allows for cell transplantation without the need for immunosuppressant drugs.

LCT's lead therapeutic candidate DIABECCELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECCELL is currently in Phase II clinical trials in both New Zealand and Argentina.

In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A\$50m on formation, LCT vested the DIABECCELL product and associated IP into the JV, while OPF vested A\$25m to fund the final phase of development of DIABECCELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECCELL and the associated IP.

LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson's disease and stroke. NTCELL's trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.

LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

## LCT Disclaimer

*This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential", "seeking to," "goal," "could "provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.*